Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

CLRB / Cellectar Biosciences, Inc. 8-K (Current Report)

2018-02-08 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________   FORM 8-K ___________________   CURRENT REPORT   PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of Report: February 8, 2018 (Date of earliest event reported)   CELLECTAR BIOSCIENCES, INC. (Exact name of registrant as specified in its charter)   Delaware 1-36598 04-3321804 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identificatio

CLRB / Cellectar Biosciences, Inc. FORM 8-K (Current Report)

2018-02-07 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       FORM 8-K       CURRENT REPORT   PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of Report: February 7, 2018 (Date of earliest event reported)   CELLECTAR BIOSCIENCES, INC. (Exact name of registrant as specified in its charter)   Delaware   1-36598   04-3321804 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification Number)   3301 Agric

CLRB / Cellectar Biosciences, Inc. FORM 8-K (Current Report)

2018-01-29 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________   FORM 8-K ___________________   CURRENT REPORT   PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of Report: January 29, 2018 (Date of earliest event reported)   CELLECTAR BIOSCIENCES, INC. (Exact name of registrant as specified in its charter)   Delaware 1-36598 04-3321804 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identificatio

Cellectar Initiates DLBCL Cohort in Phase 2 Trial of CLR 131 in Refractory B-Cell Hematologic Cancers Nasdaq:CLRB

2018-01-29 globenewswire
MADISON, Wis., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that it has enrolled the first patient in the diffuse large B-cell lymphoma (DLBCL) cohort of its Phase 2 clinical trial of CLR 131, its lead radiotherapeutic Phospholipid Drug ConjugateTM (PDCTM). (17-0)

CLRB / Cellectar Biosciences, Inc. FORM 8-K (Current Report)

2018-01-23 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________   FORM 8-K ___________________   CURRENT REPORT   PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of Report: January 22, 2018 (Date of earliest event reported)   CELLECTAR BIOSCIENCES, INC. (Exact name of registrant as specified in its charter)   Delaware 1-36598 04-3321804 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identificatio

CLRB / Cellectar Biosciences, Inc. FORM 8-K (Current Report)

2018-01-08 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________   FORM 8-K ___________________   CURRENT REPORT   PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of Report: January 3, 2018 (Date of earliest event reported)   CELLECTAR BIOSCIENCES, INC. (Exact name of registrant as specified in its charter)   Delaware   1-36598   04-3321804 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Iden

CLRB / Cellectar Biosciences, Inc. FORM 8-K (Current Report)

2018-01-04 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________   FORM 8-K ___________________   CURRENT REPORT   PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of Report: January 4, 2018 (Date of earliest event reported)   CELLECTAR BIOSCIENCES, INC. (Exact name of registrant as specified in its charter)   Delaware 1-36598 04-3321804 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification

CLRB / Cellectar Biosciences, Inc. / Sabby Management, LLC - SABBY 13G-A CLRB 1.04.18 (Passive Investment)

2018-01-04 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.4)* Cellectar Biosciences Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 15117F302 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b) [X] Rule 13d-1(c) [_] Rule 13d-1(d) __________ *The remainder

CLRB / Cellectar Biosciences, Inc. / Sabby Management, LLC - SABBY 13G-A CLRB 1.04.18 (Passive Investment)

2018-01-04 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.4)* Cellectar Biosciences Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 15117F302 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b) [X] Rule 13d-1(c) [_] Rule 13d-1(d) __________ *The remainder

CLRB / Cellectar Biosciences, Inc. ER

2017-12-31 sec.gov
November 16, 2017 James V. Caruso Chief Executive Officer Cellectar Biosciences, Inc. 3301 Agriculture Drive Madison, WI 53716 Cellectar Biosciences, Inc. Registration Statement on Form S-1 Filed November 9, 2017 File No. 333-221468 Re: Dear Mr. Caruso: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration.

CLRB / Cellectar Biosciences, Inc. ESP

2017-12-31 sec.gov
CELLECTAR BIOSCIENCES, INC. 3301 Agriculture Drive Madison, WI 53716   November 17, 2017   VIA EDGAR   Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ada D. Sarmento     Re: Cellectar Biosciences, Inc.     Registration Statement on Form S-1 Filed November 9, 2017     File No. 333-221468   Ladies and Gentlemen:   Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Cellectar Biosciences, Inc.

CLRB / Cellectar Biosciences, Inc. FORM 8-K (Current Report)

2017-12-14 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________   FORM 8-K ___________________   CURRENT REPORT   PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of Report: December 14, 2017 (Date of earliest event reported)   CELLECTAR BIOSCIENCES, INC. (Exact name of registrant as specified in its charter)   Delaware 1-36598 04-3321804 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identificati

CLRB / Cellectar Biosciences, Inc. FORM 8-K (Current Report)

2017-12-06 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________   FORM 8-K ___________________   CURRENT REPORT   PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of Report: December 6, 2017 (Date of earliest event reported)   CELLECTAR BIOSCIENCES, INC. (Exact name of registrant as specified in its charter)   Delaware 1-36598 04-3321804 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identificat


CUSIP: 15117F120